Fulltext

Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome

Jang, Liuna ; Gianniou, Christina ; Ambresin, Aude ; Mantel, Irmela

In: Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, vol. 253, no. 8, p. 1211-1216

Ajouter à la liste personnelle
    Titre
    • Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome
    Auteur
    • Jang, Liuna. Department of Ophthalmology, University of Lausanne, Lausanne, Switzerland
    • Gianniou, Christina. Department of Ophthalmology, University of Lausanne, Lausanne, Switzerland
    • Ambresin, Aude. Department of Ophthalmology, University of Lausanne, Lausanne, Switzerland
    • Mantel, Irmela. Department of Ophthalmology, University of Lausanne, Lausanne, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, vol. 253, no. 8, p. 1211-1216. Springer Berlin Heidelberg
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:331299
    Summary
    Purpose: To investigate the functional outcome of eyes with neovascular AMD (nAMD) and subretinal fluid (SRF) refractory to treatment with ranibizumab. Methods: Retrospective chart review of consecutive treatment-refractory SRF in nAMD despite monthly ranibizumab injections during 12months or more. Data were evaluated for baseline characteristics, location of the refractory SRF, mean visual acuity (VA) change, number of injections, and timepoint of first complete disappearance of SRF. Results: Forty-five eyes in 44 patients (mean age of 76years) were included. The mean follow-up was 32.4months (range 12-73months). The mean number of injections was 11.6 in the first year and 27.5 over follow-up. The refractory SRF was located subfoveally in 66.7%. In 12 eyes (26.7%), complete absorption of SRF was found after a mean of 22.6months (range, 13-41months). Mean VA increased by 10.4, 8.2, and 8.6 letters by month 12, 24, and 36, respectively. Conclusions: Neovascular AMD with SRF refractory to monthly retreatment with ranibizumab may still allow good and maintained visual improvement, even if the fluid is located subfoveally. SRF may progressively absorb under continuous monthly treatment. The necessity to treat refractory SRF with monthly injections could be questioned and would need future investigations.